Specify a stock or a cryptocurrency in the search bar to get a summary
Avidity Biosciences Inc
RNAAvidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California. Address: 10578 Science Center Drive, San Diego, CA, United States, 92121
Analytics
WallStreet Target Price
66.8 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RNA
Dividend Analytics RNA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History RNA
Stock Valuation RNA
Financials RNA
Results | 2019 | Dynamics |